dslogo
azlogo

DESTINY-Breast03: Safety Subgroup Analysis (May 21, 2021 DCO Date) 

Safety According to Disease History and Prior Lines of Therapy Subgroups11. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. Ann Oncol. 2022;33(suppl 7). Abs 236P.

Treatment Duration and Total Patient-years of Exposure to Treatment According to Subgroups.11. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. Ann Oncol. 2022;33(suppl 7). Abs 236P.

Treatment Duration and Total Patient-years of Exposure to Treatment According to Subgroups.11. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. Ann Oncol. 2022;33(suppl 7). Abs 236P.

<p>Treatment Duration and Total Patient-years of Exposure to Treatment According to Subgroups.<span class="tooltip"><span class="tooltip-text"><sup>1</sup></span><span class="tooltip-content" style="display: none;"><span>1. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. <em>Ann Oncol</em>. 2022;33(suppl 7). Abs 236P.</span></span></span></p>

Exposure-Adjusted Incidence Rates According to Subgroups.1

Exposure-Adjusted Incidence Rates According to Subgroups.1

aNumber of patients with at least 1 event incidence divided by the sum of patient-years of exposure over patients in the safety analysis set (total patient-years of exposure). Patient years of exposure are the treatment duration with year as unit.

Exposure-Adjusted Incidence Rates According to Subgroups.11. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. Ann Oncol. 2022;33(suppl 7). Abs 236P.

Exposure-Adjusted Incidence Rates According to Subgroups.11. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. Ann Oncol. 2022;33(suppl 7). Abs 236P.

<p>Exposure-Adjusted Incidence Rates According to Subgroups.<span class="tooltip"><span class="tooltip-text"><sup>1</sup></span><span class="tooltip-content" style="display: none;"><span>1. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. <em>Ann Oncol</em>. 2022;33(suppl 7). Abs 236P.</span></span></span></p>

aNumber of patients with at least 1 event incidence divided by the sum of patient-years of exposure over patients in the safety analysis set (total patient-years of exposure). Patient years of exposure are the treatment duration with year as unit.

Abbreviations

DCO = data cutoff

;

HER2 = human epidermal growth factor receptor 2

;

mBC = metastatic breast cancer

;

T-DM1 = trastuzumab emtansine

;

T-DXd = trastuzumab deruxtecan

;

TEAE = treatment emergent adverse event

References

1. Cortés J, Im SA, Iwata H, et al. Subgroup analysis by disease history and prior treatments of patients with HER2-positive metastatic breast cancer from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan vs trastuzumab emtansine [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress 2022; September 9-13, 2022. Ann Oncol. 2022;33(suppl 7). Abs 236P.

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

©2023 AstraZeneca. All rights reserved.